Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Parathyroid Hormone Market Size Shifted, And What Is the Outlook Through 2034?

In the past few years, the market size for the parathyroid hormone has seen a consistent expansion. It is projected to increase from $2.35 billion in 2024 to $2.43 billion in 2025 with a compound annual growth rate (CAGR) of 3.5%. The considerable growth in the previous years can be linked to the increasing incidence of chronic kidney disease, heightened awareness about disorders related to the parathyroid hormone, an uptick in the demand for parathyroid hormone analogs, more government resources allocated for research on the parathyroid hormone, and a rise in disposable incomes.

How Much Will the Parathyroid Hormone Market Be Worth in 2029?

Anticipated to exhibit significant growth in the forthcoming years, the parathyroid hormone market size is projected to escalate to $3.5 billion by 2029 with a compound annual growth rate (CAGR) of 9.6%. This predicted growth during the forecasted period originates from factors including an increasing elderly population, expansion in the private healthcare sectors, emerging indications, precision medicine, augmented awareness of bone health, along with widened healthcare accessibility. Important trends expected to influence the market in the forecast period incorporate advances in parathyroid hormone testing procedures, improvements in drug delivery, integrated therapies, the inclusion of digital health, and the promotion of sustainability and green initiatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3427&type=smp

Which is the Largest Company in the Parathyroid Hormone Market?

Major companies operating in the parathyroid hormone market include Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, Cipla Limited

What Are the Main Market Drivers in the Parathyroid Hormone Industry?

An increased incidence of osteoporosis is anticipated to fuel the demand for parathyroid hormones in the marketplace. Osteoporosis is a health condition identified by a decrease in bone density and degradation of bone tissue, leading to a heightened propensity towards fractures. Data from the International Osteoporosis Foundation in January 2023 revealed that roughly 1.4 million Canadians, primarily postmenopausal women and seniors, are affected by osteoporosis. The parathyroid hormone, a naturally occurring body hormone responsible for controlling calcium amounts, is utilized to minimize the likelihood of bone fractures in osteoporosis patients and is given as a daily subcutaneous shot. Therefore, the escalating cases of osteoporosis are projected to bolster the expansion of the parathyroid hormone market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3427&type=smp

How Is the Parathyroid Hormone Market Segments Structured?

The parathyroid hormone market covered in this report is segmented –

1) By Disease Type: Hypocalcemia, Hypoparathyroidism

2) By Product Type: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues

3) By End-User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Hypocalcemia: Pseudohypoparathyroidism, Vitamin D Deficiency

2) By Hypoparathyroidism: Post-Surgical Hypoparathyroidism, Idiopathic Hypoparathyroidism

What Strategic Trends Are Transforming the Parathyroid Hormone Market?

Leading firms in the parathyroid hormone market are concentrating their efforts on innovating biosimilars of parathyroid-based medications, such as parathyroid hormone prodrugs, to expand treatment possibilities. A PTH prodrug is a dormant compound that becomes an active parathyroid hormone once administered. This transformation allows for an extended release and consistent therapeutic results for calcium balance and bone health. In August 2024, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, reported that the Food & Drug Administration (FDA) granted approval to YORVIPATH (palopegteriparatide), making it the sole treatment for adult hypoparathyroidism. This daily prodrug delivers constant PTH exposure, which is beneficial to an estimated 70,000 to 90,000 U.S. patients. Ascendis Pharma, the producer of the drug, offers patient assistance through its Ascendis Signature Access Program (A.S.A.P.), but bear in mind that users need to consistently check their serum calcium levels due to the possibility of hypercalcemia or hypocalcemia.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Which Global Regions Offer the Highest Growth in the Parathyroid Hormone Market?

The countries covered in the parathyroid hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3427

This Report Delivers Insight On:

1. How big is the parathyroid hormone market, and how is it changing globally?

2. Who are the major companies in the parathyroid hormone market, and how are they performing?

3. What are the key opportunities and risks in the parathyroid hormone market right now?

4. Which products or customer segments are growing the most in the parathyroid hormone market?

5. What factors are helping or slowing down the growth of the parathyroid hormone market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model